Biotech Strategy questions answered on BRAF, MEK, immunotherapy, mirvetuximab soravtansine and venetoclax

This month's Biotech Strategy Blog mail bag.

July 17, 2015

Update on resistance and transformation in lung cancer

As we learn more about mechanisms of resistance in ALK+ and T790M mutated lung cancer, combination strategies are likely to evolve - but which ones?

July 9, 2015

Targeting MYC – the undruggable protein – or is it?

Targeting MYC and bromodomains is an emerging area of research as we learn more about super enhancer transcription factor clusters around oncogenes that drive cancer.

May 26, 2015

What happens when you combine checkpoint blockade with an immune stimulant in cancer?

What happens when we combine a checkpoint with an immune stimulant in advanced melanoma?

May 6, 2015

AACR Gems from the Poster Halls in ImmunoOncology

Beyond monotherapy with checkpoint inhibition, what combinations or sequences might be useful to explore next?

April 28, 2015

Are targeted therapies now a thing of the past in the immunotherapy era?

New developments in T790M and ALK lung cancer plus a look at antibodies targeting ADAM17 in head & neck cancer.

April 27, 2015

Where are checkpoint inhibitors going next?

Beyond lung cancer and melanoma, what other tumour types represent the low hanging fruit for checkpoint monotherapy?

April 24, 2015

Is this the end of ipilimumab in melanoma?

As the anti-PD-1 blockers show superiority in front-line metastatic melanoma, is this the end for Yervoy?

April 23, 2015

Top 10 Highlights of AACR 2015

The annual meeting of the American Association for Cancer Research ended today. Find out what were our top 10 highlights.

April 22, 2015

Checkpoint Inhibitor Data Rocks AACR 2015

Checkpoint Inhibitor data is a hot topic at AACR 2015. Data showed they may work in TNBC and also two checkpoints are better than one.

April 21, 2015

Reflections on AACR 2015 Cancer Immunotherapy Data

Cancer Immunotherapy is one of the hot topics at the 2015 AACR annual meeting in Philadelphia.

April 20, 2015

UCL Drives CD19 CAR T Cell Therapy Forward in Europe

University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.

April 14, 2015

Novel Combination Approaches with Checkpoint Inhibitors

Emerging data on different combinations with checkpoint inhibitors suggests that this may increase response rates and outcomes for cancer patients. Find out more...

March 31, 2015

What is STING and why does it matter in cancer immunotherapy?

Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.

March 30, 2015

How do we improve responses to checkpoint inhibitors in lung cancer?

The mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

March 26, 2015

Cellular therapy with EBV-CTL reduces death post stem cell transplant

What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?

March 20, 2015

Emerging new biomarker for predicting checkpoint inhibitor responders

Predictive biomarkers of response will be key to reimbursement of immunotherapies in Europe. One is potentially emerging for ipilimumab (Yervoy), which may be useful in speeding up access.

March 19, 2015

AACR 2015 Cancer Immunotherapy Preview

What are the emerging new trends in cancer immunotherapy? Beyond monotherapy lies many combination opportunities yet to be explored. At AACR in April, we will see a raft of novel approaches being discussed.

March 11, 2015